BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 33223089)

  • 1. Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke.
    Gonzalez JB; Testai FD
    Neurol Clin; 2021 Feb; 39(1):51-69. PubMed ID: 33223089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances and ongoing controversies in PFO closure and cryptogenic stroke.
    Cheng T; Gonzalez JB; Testai FD
    Handb Clin Neurol; 2021; 177():43-56. PubMed ID: 33632456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
    Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
    Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
    Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
    Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
    Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
    Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Patent Foramen Ovales Need Closure to Prevent Cryptogenic Strokes?
    Dalen JE; Alpert JS
    Am J Med; 2018 Mar; 131(3):222-225. PubMed ID: 29175238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Patients With Cryptogenic Cerebrovascular Events Undergoing Transcatheter Closure of Patent Foramen Ovale.
    Farjat-Pasos JI; Guedeney P; Houde C; Alperi A; Robichaud M; Côté M; Montalescot G; Rodés-Cabau J
    J Am Heart Assoc; 2023 Oct; 12(19):e030359. PubMed ID: 37776218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update.
    Abdelghani M; El-Shedoudy SAO; Nassif M; Bouma BJ; de Winter RJ
    Cardiology; 2019; 143(1):62-72. PubMed ID: 31307049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptogenic stroke in patients with patent foramen ovale.
    Saver JL
    Curr Atheroscler Rep; 2007 Oct; 9(4):319-25. PubMed ID: 18173960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke.
    Low CE; Teo YN; Teo YH; Lim ICZ; Rana S; Lee YQ; Chen X; Fang JT; Lam HH; Ong K; Yang J; Kuntjoro I; Low TT; Lee EC; Sharma VK; Yeo LL; Sia CH; Tan BY; Lim Y
    J Stroke Cerebrovasc Dis; 2023 Dec; 32(12):107407. PubMed ID: 37804781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent foramen ovale.
    Homma S; Messé SR; Rundek T; Sun YP; Franke J; Davidson K; Sievert H; Sacco RL; Di Tullio MR
    Nat Rev Dis Primers; 2016 Jan; 2():15086. PubMed ID: 27188965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment.
    Melkumova E; Thaler DE
    Interv Cardiol Clin; 2017 Oct; 6(4):487-493. PubMed ID: 28886840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptogenic Strokes and Patent Foramen Ovales: What's the Right Treatment?
    Dalen JE; Alpert JS
    Am J Med; 2016 Nov; 129(11):1159-1162. PubMed ID: 27566504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design.
    Khattab AA; Windecker S; Jüni P; Hildick-Smith D; Dudek D; Andersen HR; Ibrahim R; Schuler G; Walton AS; Wahl A; Mattle HP; Meier B
    Trials; 2011 Feb; 12():56. PubMed ID: 21356042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcranial Doppler Screening for Patent Foramen Ovale Closure in Cryptogenic Strokes in Young: A Single Center Experience from South India.
    Bal D; Ahmed Shaikh AI; Rayani M; Aaron S; Thompson VS; Jose J; Krupa J; Benjamin RN; Rajkumar JL; Prabhakar AT
    J Assoc Physicians India; 2022 Oct; 70(10):11-12. PubMed ID: 37355867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.